Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL8018930 | 0.86 | — | — | |
| Ethylene Glycol SCHEMBL19742049 | 0.86 | — | — | |
| Ethylene Glycol SCHEMBL8167017 | 0.86 | — | — | |
| Ethylene Glycol SCHEMBL8958886 | 0.86 | — | — | |
| Ethylene Glycol SCHEMBL2860028 | 0.86 | — | — | |
| Ethylene Glycol SCHEMBL8986295 | 0.86 | TSHR (0.71) | TSHRALDH1A1TDP1MAPK1 | |
| Ethylene Glycol SCHEMBL11049087 | 0.86 | — | — | |
| Ethylene Glycol SCHEMBL8013339 | 0.84 | TSHR (1.00) | TSHRALDH1A1TDP1MAPK1 | |
| Ethylene Glycol SCHEMBL3 | 0.84 | — | — | |
| Ethylene Glycol SCHEMBL1332716 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232084-A1 | Administering parenterally effective dose of iron oxide complex with polyol or polyether formulated in biocompatible liquid so that upon administration provides minimal detectable free iron in and minimal incidence of anaphylaxis | COVIS PHARMA GMBH (CH) | 2003-12-18 | — | — | US | claimed |
| US-9555133-B2 | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents | AMAG PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-8926947-B2 | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents | AMAG PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140296509-A1 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents | AMAG PHARMACEUTICALS, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140178310-A1 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents | AMAG PHARMACEUTICALS, INC. | 2014-06-26 | — | — | US | disclosed |
| US-8591864-B2 | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents | AMAG PHARMACEUTICALS, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-8507207-B2 | Recombinant nucleotide sequence, cell or vector containing the same and method for using cell containing the same to encode anti-polyethylene glycol monoclonal antibodies | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-08-13 | — | — | US | disclosed |
| US-8501158-B2 | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents | AMAG PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130121929-A1 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents | AMAG PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20110144054-A1 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents | AMAG PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110064651-A1 | RECOMBINANT NUCLEOTIDE SEQUENCE, CELL OR VECTOR CONTAINING THE SAME AND METHOD FOR USING CELL CONTAINING THE SAME TO ENCODE ANTI-POLYETHYLENE GLYCOL MONOCLONAL ANTIBODIES | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2011-03-17 | — | — | US | disclosed |
| US-7871597-B2 | Administering parenterally effective dose of iron oxide complex with polyol or polyether formulated in biocompatible liquid so that upon administration provides minimal detectable free iron in and minimal incidence of anaphylaxis | AMAG PHARMACEUTICALS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20030232084-A1 | Administering parenterally effective dose of iron oxide complex with polyol or polyether formulated in biocompatible liquid so that upon administration provides minimal detectable free iron in and minimal incidence of anaphylaxis | COVIS PHARMA GMBH (CH) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130121929-A1 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents | TFRC, MSR1, CD47 | TSHR 1635/4885ALDH1A1 3603/4885TDP1 4533/4885 |
| US-20140178310-A1 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents | TFRC, MSR1, CD47 | TSHR 1635/4885ALDH1A1 3603/4885TDP1 4533/4885 |
| US-20030232084-A1 | Administering parenterally effective dose of iron oxide complex with polyol or polyether formulated in biocompatible liquid so that upon administration provides minimal detectable free iron in and minimal incidence of anaphylaxis | TFRC, CMA1, CD69 | TSHR 1893/4885ALDH1A1 4159/4885TDP1 4406/4885 |
| US-20110144054-A1 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents | TFRC, CD69, CMA1 | TSHR 1487/4885ALDH1A1 4653/4885TDP1 4121/4885 |
| US-20140296509-A1 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents | TFRC, MSR1, CD47 | TSHR 1635/4885ALDH1A1 3603/4885TDP1 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.